Clinical Trial Update: ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ARQ 501 in combination with gemcitabine for pancreatic adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• ARQ 501
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Pancreatic Cancer, Adenocarcinoma | Phase 2 | Status: COMPLETED